Psoriasis and infection. A clinical practice narrative

M Rademaker, K Agnew, N Anagnostou… - Australasian Journal …, 2019 - Wiley Online Library
Abstract The Australasian Psoriasis Collaboration has developed a clinical practice
narrative with respect to the relationship between psoriasis, its treatment and infection. The …

Liver illness and psoriatic patients

M Fiore, S Leone, AE Maraolo, E Berti… - BioMed Research …, 2018 - Wiley Online Library
Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the
world's population. Systemic treatments, including methotrexate and cyclosporin, are …

Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian …

JLW Lambert, S Segaert, PD Ghislain… - Journal of the …, 2020 - Wiley Online Library
Background Psoriasis patients carry an increased risk for associated comorbidities.
Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis …

[PDF][PDF] S3‐Leitlinie zur Therapie der Psoriasis vulgaris Update 2011

A Nast, WH Boehncke, U Mrowietz… - JDDG: Journal der …, 2011 - psoriasis-rheinruhr.de
1.1 Bedarfsanalyse/Probleme in der Versorgung der Patienten Die Psoriasis vulgaris stellt
eine häufige und fast immer chronisch verlaufende dermatologische Erkrankung dar. Die …

Managing psoriasis in patients with HBV or HCV infection: practical considerations

S Piaserico, F Messina, FP Russo - American Journal of Clinical …, 2019 - Springer
Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …

[PDF][PDF] TNF inhibitors for psoriasis

M Chima, M Lebwohl - Semin Cutan Med Surg, 2018 - scmsjournal.com
■ Abstract Tumor necrosis factor (TNF)-α has been identified as a key cytokine mediating
cutaneous inflammation in the pathogenesis of psoriasis. The TNF inhibitors (TNFi's) …

Treatment of psoriasis with secukinumab in challenging patient scenarios: a review of the available evidence

JJ Wu, JF Merola, SR Feldman, A Menter… - Dermatology and …, 2020 - Springer
Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key
clinical symptoms, including itching, pain, and scaling. PsO is associated with a high …

INASL guidelines on management of hepatitis B virus infection in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids

A Arora, AC Anand, A Kumar, SP Singh… - Journal of clinical and …, 2018 - Elsevier
Hepatitis B Virus (HBV) reactivation in patients receiving chemotherapy, biologicals,
immunosupressants, or corticosteroids is emerging to be an important cause of morbidity …

Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID‑19

L Baroiu, L Anghel, AL Tatu… - Experimental and …, 2022 - spandidos-publications.com
The cytokine storm from the evolution of severe cases of COVID‑19, requiring strong
immunosuppressive therapies, has raised the issue of reactivation of hepatitis B virus (HBV) …

[HTML][HTML] Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct …

G Damiani, C Franchi, P Pigatto… - World Journal of …, 2018 - ncbi.nlm.nih.gov
AIM To evaluate the outcomes in biological treatment and quality of life of psoriatic patients
with chronic hepatitis C (CHC) treated with new Direct-Acting Antiviral agents (DAAs) …